The products, AMPLEX and PREFIX, are designed to improve bone repair. The initial indications to be investigated are fusion in foot or ankle procedures for AMPLEX and lumbar spine surgical procedures for PREFIX. Both products are based on a biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair. They are ready to enter phase III of clinical trials, when the product is given to large groups of people to confirm its effectiveness and monitor side effects.
“By developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopedic surgery,” said Michel Pettigrew, president of the Ferring Executive Board and COO.
More articles on devices:
5 quick notes on Precision Spine’s MD-Max ULIF System: Dr. Donald Kucharzyk
LDR’s 4Q revenue up 23.6%: 12 key notes
Orthocell’s expands Asia presence; tendon repair therapy used in Hong Kong
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
